MedTrace Logo

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium.

PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.

Conditions

  • Stage IV Prostate Cancer
  • Bone Metastases
  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer

Interventions

DRUG

alendronate sodium

DRUG

ketoconazole

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • William D. Figg · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019695 on ClinicalTrials.gov